The Company's 2021 consolidated financial statements have been approved by the Board of Directors
· Issued by SciVision Biotech Inc.
Close
Today's Information
Provided by: SciVision Biotech Inc.
SEQ_NO
1
Date of announcement
2022/03/23
Time of announcement
15:42:12
Subject
The Company's 2021 consolidated financial statements
have been approved by the Board of Directors
Date of events
2022/03/23
To which item it meets
paragraph 31
Statement
1.Date of submission to the board of directors or approval by the board of
directors:2022/03/23
2.Date of approval by the audit committee:2022/03/23
3.Start and end dates of financial reports or annual self-assessed financial
information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):505,539
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):341,836
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):121,942
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):116,055
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):101,720
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):101,720
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):1.54
11.Total assets end of the period (thousand NTD):2,261,942
12.Total liabilities end of the period
(thousand NTD):812,061
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,449,881
14.Any other matters that need to be specified:None
